VYNE Therapeutics (NASDAQ:VYNE) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note released on Wednesday,Benzinga reports. The firm currently has a $5.75 price objective on the stock.

Separately, BTIG Research initiated coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price objective for the company.

VYNE Therapeutics Stock Up 1.5 %

Shares of NASDAQ VYNE opened at $2.74 on Wednesday. The firm’s 50-day simple moving average is $2.82 and its 200 day simple moving average is $2.46. The company has a market cap of $40.42 million, a price-to-earnings ratio of -3.19 and a beta of 1.28. VYNE Therapeutics has a 12-month low of $1.57 and a 12-month high of $4.30.

Insiders Place Their Bets

In other news, Director Patrick G. Lepore acquired 15,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was purchased at an average cost of $2.92 per share, with a total value of $43,800.00. Following the acquisition, the director now owns 51,472 shares of the company’s stock, valued at $150,298.24. This trade represents a 41.13 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.80% of the company’s stock.

Institutional Trading of VYNE Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VYNE. Jane Street Group LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter valued at about $68,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter valued at about $823,000. Bridgeway Capital Management LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter valued at about $124,000. Schonfeld Strategic Advisors LLC increased its stake in shares of VYNE Therapeutics by 4.8% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after acquiring an additional 8,058 shares during the last quarter. Finally, Acorn Capital Advisors LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter valued at about $1,531,000. 83.78% of the stock is owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.